Patents Represented by Attorney Peter J. Waibel
-
Patent number: 7271168Abstract: The invention provides compounds of formula (1) wherein X, R1 and R2 are as defined in the specification, their, preparation and to their use in treating, e.g., depression, anxiety and bipolar disorders.Type: GrantFiled: November 8, 2002Date of Patent: September 18, 2007Assignee: Novartis AGInventors: Thomas J. Troxler, Daniel Hoyer
-
Patent number: 7253257Abstract: The invention provides purified human metabotropic glutamate receptors, compositions comprising such receptors, and nucleic acids that encode such receptors.Type: GrantFiled: December 30, 2002Date of Patent: August 7, 2007Assignee: Novartis CorporationInventors: Peter Josef Flor, Rainer Kuhn, Kristin Lindauer, Irene Püttner, Thomas Knöpfel
-
Patent number: 7202364Abstract: Compounds of formula (I) wherein R is hydrogen, lower alkyl, (C3–C6)cycloalkyl, hydroxy, halo, lower alkoxy, trifluoromethoxy, trifluoromethyl or cyano; and A is biaryl, optionally substituted ?-naphthyl, bicyclic heterocyclic aryl, (C3–C6)cycloalkyl-monocyclic carbocyclic aryl, or (C5 or C6)cycloalkane fused-monocyclic carbocyclic aryl; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable esters thereof; which are useful for the treatment of COX-2 dependent disorders.Type: GrantFiled: November 25, 2003Date of Patent: April 10, 2007Assignee: Novartis, AGInventors: Roger A. Fujimoto, Leslie W. McQuire, Lauren G. Monovich, Benjamin B. Mugrage, David T. Parker, John H. VanDuzer, Sompong Wattanasin
-
Patent number: 7138405Abstract: Pharmaceutical combinations suitable for treating the lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in men are described herein. The combinations contain an alpha-adrenoceptor antagonist and a muscarinic antagonist that may be administered simultaneously, separately or sequentially. The methods of treatment using the combinations are particularly suitable for treating moderate or severe LUTS.Type: GrantFiled: May 31, 2005Date of Patent: November 21, 2006Assignee: Novartis International Pharmaceutical LtdInventor: Michael G Wyllie
-
Patent number: 7119189Abstract: The present invention provides purified GABAB receptors and receptor proteins derived from rat and human sources, as well as nucleic acids which encode such proteins. The proteins and nucleic acids of the invention share significant homology with the GABAB receptor and the DNA encoding it as specifically disclosed herein. The invention moreover provides methods for isolating other members of the GABAB receptor family using DNA cloning technology and probes derived from the sequences provided herein, as well as novel members of the GABAB receptor family isolated by such methods.Type: GrantFiled: June 6, 2001Date of Patent: October 10, 2006Assignee: Novartis AGInventors: Klemens Kaupmann, Bernhard Bettler, Helmut Bittiger, Wolfgang Fröstl, Stuart J Mickel
-
Patent number: 7115662Abstract: Disclosed are the compounds of formula I wherein R is methyl or ethyl; R1 is chloro or fluoro; R2 is hydrogen or fluoro; R3 is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy; R4 is hydrogen or fluoro; and R5 is chloro, fluoro, trifluoromethyl or methyl; and pharmaceutically acceptable salts thereof, as selective COX-2 cyclooxygenase inhibitors; and pharmaceutically acceptable prodrug esters thereof.Type: GrantFiled: December 4, 2003Date of Patent: October 3, 2006Assignee: Novartis AGInventors: Roger A Fujimoto, Leslie W McQuire, Benjamin B Mugrage, John H Van Duzer, Daqiang Xu
-
Patent number: 7112673Abstract: The invention relates to new processes for the preparation of the pharmaceutical oxcarbazepine, as well as novel intermediates prepared by or used for said processes, and the preparation of said intermediates.Type: GrantFiled: February 7, 2001Date of Patent: September 26, 2006Assignee: Novartis AGInventors: Peter Funfschilling, Daniel Kaufmann, Olivier Lohse, Ulrich Beutler, Werner Zaugg
-
Patent number: 7109203Abstract: Sulfonamide derivitives of the formula I wherein R1-R6 are as defined in the description, processes for their production, their use as pharmaceuticals, particularly for use in the treatment or prevention of diseases in which bradykinin B1 receptor activation plays a role or is implicated, and pharmaceutical compositions comprising themType: GrantFiled: May 13, 2002Date of Patent: September 19, 2006Assignee: Novartis AGInventors: Terance W Hart, Timothy J Ritchie
-
Patent number: 7087756Abstract: The invention provides compounds of formula I, wherein X, Y, R1, R2, and R3 are as defined in the description, and the preparation thereof. The compounds of formula I are useful as pharmaceuticals.Type: GrantFiled: August 14, 2002Date of Patent: August 8, 2006Assignee: Novartis AGInventors: Samuel Hintermann, Bastian Hengerer, Ulrike Von Krosigk
-
Patent number: 7049283Abstract: Solid pharmaceutical compositions suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions provide excellent oral bioavailability of pharmacologically active agents, particularly calcitonin.Type: GrantFiled: December 4, 2001Date of Patent: May 23, 2006Assignee: Novartis AGInventors: Joseph M. Ault, Moise Azria, Simon David Bateman, Joseph Sikora, Gregory Sparta, Rebecca Fai-ying Yang, Jie Xiao
-
Patent number: 7045533Abstract: The present invention relates to novel naphthalene derivatives of formula (I), wherein R1, R2, R3 and X are as defined in the description, and preparation thereof. The compounds of formula (I) are useful as pharmaceuticals.Type: GrantFiled: November 22, 2001Date of Patent: May 16, 2006Assignee: Novartis AGInventors: Christopher T Brain, Andrew J Culshaw, Edward K Dziadulewicz, Ulrich Schopfer
-
Patent number: 7037525Abstract: The invention relates to formulations, e.g. film-coated tablets containing oxcarbazepine and to processes for the production of said formulations. The film-coated tablets have a tablet core comprising a therapeutically effective dose of oxacarbazepine being in a finely ground form having a mean particle size of from 4 to 12 ?m (median value), and a hydrophilic permeable outer coating.Type: GrantFiled: May 5, 2003Date of Patent: May 2, 2006Assignee: Novartis AGInventor: Burkhard Schlütermann
-
Patent number: 7019004Abstract: The invention provides compounds of formula (I) wherein X, Y, R1, R2, R3 and R4 are as defined in the description, and the preparation thereof.Type: GrantFiled: May 7, 2001Date of Patent: March 28, 2006Assignee: Novartis AGInventors: Daniel Berney, Robin Breckenridge, Peter Neumann, Gideon Shapiro, Max Peter Seiler, Thomas J. Troxler
-
Patent number: 6727243Abstract: Cefuroxime axetil in a non-gelatinous form on contact with an aqueous liquid, e.g., in the form of a solid dispersion on a carrier, e.g., useful for the production of pharmaceutical compositions comprising cefuroxime axetil as an active ingredient and use of cefuroxime axetil in the manufacture of an oral dosage form which does not exhibit an adverse food effect.Type: GrantFiled: December 10, 1999Date of Patent: April 27, 2004Assignee: Biochemie Gesellschaft m.b.H.Inventors: Herwig Jennewein, Johannes Raneburger
-
Patent number: 6693095Abstract: A compound of formula wherein W, V, R1, R5, R2, R3 and R4 have various meanings, a process for their production and their use as a pharmaceutical.Type: GrantFiled: November 13, 2001Date of Patent: February 17, 2004Assignee: Biochemie Gesellschaft m.b.H.Inventors: Gerd Ascher, Josef Wieser, Michael Schranz, Johannes Ludescher, Johannes Hildebrandt
-
Patent number: 6518420Abstract: A process in the isolation of 7-aminocephalosporanic acid (7-ACA) from an alkaline, neutral or slightly acidic medium in the presence of an additive, e.g. selected from the group comprising organic carboxylic acid esters, polymeric glycols, polyacryls, amines and polyamines, melaminformaldehyde resins or amino acids and esters thereof to obtain 7-ACA agglomerates and or rosettes.Type: GrantFiled: November 7, 2001Date of Patent: February 11, 2003Assignee: Biochemie Gesellschaft m.b.H.Inventors: Petr Nadenik, Helmut Wagner
-
Patent number: 6504026Abstract: Process for preparing ceftiofur having formula I: in the form of the sodium salt.Type: GrantFiled: November 20, 2001Date of Patent: January 7, 2003Assignee: Biochemie Gesellschaft m.b.H.Inventors: Andreas Berger, Martin Decristoforo, Johannes Ludescher, Herbert Schleich
-
Patent number: 6468996Abstract: The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).Type: GrantFiled: October 19, 1999Date of Patent: October 22, 2002Assignees: Novo Nordisk A/S, Dr. Reddy's Research FoundationInventors: Lone Jeppesen, Paul Stanley Bury, Per Sauerberg
-
Patent number: 6417218Abstract: A class of substituted imidazole compounds of formula I methods for their preparation, pharmaceutical compositions comprising them and use thereof in the treatment of disorders related to the histamine H3 receptor are disclosed. More particularly, these compounds possess histamine H3 receptor antagonistic activity and are thus useful for the treatment of disorders in which a histamine H3 receptor blockade is beneficial.Type: GrantFiled: January 18, 2000Date of Patent: July 9, 2002Assignees: Novo Nordisk A/S, Boehringer Ingelheim International GmbHInventors: Florencio Zaragoza Dorwald, Knud Erik Andersen
-
Patent number: 6410743Abstract: Tetrahydronaphatalene derivatives, and compositions comprising the compounds. The tetrahydronaphatalene derivates are useful in inhibiting a rise in intracellular calcium mediated by an influx through T-type calcium channels, and are thus useful for treatment of, for example, type 1 and type 2 diabetes and cardiovascular diseases associated with diabetes.Type: GrantFiled: March 27, 2001Date of Patent: June 25, 2002Assignees: Novo Nordisk A/S, South Alabama Medical Science FoundationInventors: Ming Li, John Bondo Hansen, Tina Moller Tagmose